

Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

IRAK4 Antibody

RRID:AB_2126429

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4363, RRID:AB_2126429

Antibody Information

URL: http://antibodyregistry.org/AB_2126429

Proper Citation: Cell Signaling Technology Cat# 4363, RRID:AB_2126429

Target Antigen: IRAK4

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10695155, AB_10839262, AB_2126429.

Antibody Name: IRAK4 Antibody

Description: This unknown targets IRAK4

Target Organism: rat, mouse, human

Antibody ID: AB_2126429

Vendor: Cell Signaling Technology

Catalog Number: 4363

Record Creation Time: 20250820T005509+0000

Record Last Update: 20250820T093305+0000

Ratings and Alerts

No rating or validation information has been found for IRAK4 Antibody.

No alerts have been found for IRAK4 Antibody.

Data and Source Information

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Wu MM, et al. (2026) Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under immune checkpoint blockade. *Cell metabolism*, 38(1), 208.

Sun HJ, et al. (2025) Phosphoglycerate kinase 1 contributes to diabetic kidney disease through enzyme-dependent and independent manners. *Cell reports. Medicine*, 6(8), 102241.

Campbell GR, et al. (2023) IRAK1 inhibition blocks the HIV-1 RNA mediated pro-inflammatory cytokine response from microglia. *The Journal of general virology*, 104(5).

Campbell GR, et al. (2022) Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA. *Journal of innate immunity*, 1.

Qiu W, et al. (2021) Identification and characterization of a novel adiponectin receptor agonist adipo anti-inflammation agonist and its anti-inflammatory effects in vitro and in vivo. *British journal of pharmacology*, 178(2), 280.

Liang K, et al. (2017) Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. *Cell*, 168(1-2), 59.